Search

Your search keyword '"Goldberg, Aaron D"' showing total 361 results
Start Over Author "Goldberg, Aaron D"
361 results on '"Goldberg, Aaron D"'

1. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, Nanaa, Ahmad, Atallah, Ehab, Shallis, Rory M., Guilherme, Sacchi de Camargo Correia, Goldberg, Aaron D., Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., DuVall, Adam S., Bradshaw, Danielle, Abaza, Yasmin, Murthy, Guru Subramanian Guru, Palmisiano, Neil, Zeidan, Amer M., Kota, Vamsi, and Litzow, Mark R.

Published
2024
Full Text
View/download PDF

2. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Author

Shimony, Shai, Bewersdorf, Jan Philipp, Shallis, Rory M., Liu, Yiwen, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

3. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Garciaz, Sylvain, Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

5. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, Atallah, Ehab, Shallis, Rory, Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., Grenet, Justin, Stahl, Maximilian, Duvall, Adam, Burkart, Madelyn, Palmisiano, Neil, Bradshaw, Danielle, Kubiak, Michal, Dinner, Shira, Goldberg, Aaron D., Abaza, Yasmin, Murthy, Guru Subramanian Guru, Kota, Vamsi, and Litzow, Mark R.

Published
2023
Full Text
View/download PDF

6. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Author

McCarter, Joseph G. W., Nemirovsky, David, Famulare, Christopher A., Farnoud, Noushin, Mohanty, Abhinita S., Stone-Molloy, Zoe S., Chervin, Jordan, Ball, Brian J., Epstein-Peterson, Zachary D., Arcila, Maria E., Stonestrom, Aaron J., Dunbar, Andrew, Cai, Sheng F., Glass, Jacob L., Geyer, Mark B., Rampal, Raajit K., Berman, Ellin, Abdel-Wahab, Omar I., Stein, Eytan M., Tallman, Martin S., Levine, Ross L., Goldberg, Aaron D., Papaemmanuil, Elli, Zhang, Yanming, Roshal, Mikhail, Derkach, Andriy, and Xiao, Wenbin

Published
2023
Full Text
View/download PDF

7. Single-cell mutation analysis of clonal evolution in myeloid malignancies

Author

Miles, Linde A, Bowman, Robert L, Merlinsky, Tiffany R, Csete, Isabelle S, Ooi, Aik T, Durruthy-Durruthy, Robert, Bowman, Michael, Famulare, Christopher, Patel, Minal A, Mendez, Pedro, Ainali, Chrysanthi, Demaree, Benjamin, Delley, Cyrille L, Abate, Adam R, Manivannan, Manimozhi, Sahu, Sombeet, Goldberg, Aaron D, Bolton, Kelly L, Zehir, Ahmet, Rampal, Raajit, Carroll, Martin P, Meyer, Sara E, Viny, Aaron D, and Levine, Ross L

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Biotechnology, Rare Diseases, Genetics, Clinical Research, Hematology, Cancer, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Cell Separation, Clone Cells, DNA Mutational Analysis, Humans, Immunophenotyping, Mutation, Myeloproliferative Disorders, Single-Cell Analysis, General Science & Technology
Abstract

Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukaemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later1-3. Although bulk sequencing can provide information about leukaemia biology and prognosis, it cannot distinguish which mutations occur in the same clone(s), accurately measure clonal complexity, or definitively elucidate the order of mutations. To delineate the clonal framework of myeloid malignancies, we performed single-cell mutational profiling on 146 samples from 123 patients. Here we show that AML is dominated by a small number of clones, which frequently harbour co-occurring mutations in epigenetic regulators. Conversely, mutations in signalling genes often occur more than once in distinct subclones, consistent with increasing clonal diversity. We mapped clonal trajectories for each sample and uncovered combinations of mutations that synergized to promote clonal expansion and dominance. Finally, we combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Our findings provide insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.

Published
2020

8. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Author

Garcia-Manero, Guillermo, Goldberg, Aaron D, Winer, Eric S, Altman, Jessica K, Fathi, Amir T, Odenike, Olatoyosi, Roboz, Gail J, Sweet, Kendra, Miller, Crystal, Wennborg, Anders, Hickman, Denice K, Kanagal-Shamanna, Rashmi, Kantarjian, Hagop, Lancet, Jeffrey, Komrokji, Rami, Attar, Eyal C, and Sallman, David A

Published
2023
Full Text
View/download PDF

9. TP53 Y220C mutations in patients with myeloid malignancies

Author

Gener-Ricos, Georgina, primary, Bewersdorf, Jan P., additional, Loghavi, Sanam, additional, Bataller, Alex, additional, Goldberg, Aaron D., additional, Famulare, Christopher, additional, Takahashi, Koichi, additional, Issa, Ghayas C., additional, Borthakur, Gautam, additional, Kadia, Tapan M., additional, Short, Nicholas J., additional, Senapati, Jayastu, additional, Carter, Bing Z., additional, Patel, Keyur P., additional, Kantarjian, Hagop, additional, Andreeff, Michael, additional, Stein, Eytan M., additional, and DiNardo, Courtney D., additional

Published
2024
Full Text
View/download PDF

11. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

Author

Xiao, Wenbin, Chan, Alexander, Waarts, Michael R., Mishra, Tanmay, Liu, Ying, Cai, Sheng F., Yao, Jinjuan, Gao, Qi, Bowman, Robert L., Koche, Richard P., Csete, Isabelle S., DelGaudio, Nicole L., Derkach, Andriy, Baik, Jeeyeon, Yanis, Sophia, Famulare, Christopher A., Patel, Minal, Arcila, Maria E., Stahl, Maximilian, Rampal, Raajit K., Tallman, Martin S., Zhang, Yanming, Dogan, Ahmet, Goldberg, Aaron D., Roshal, Mikhail, and Levine, Ross L.

Published
2021
Full Text
View/download PDF

12. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Author

Stahl, Maximilian, Menghrajani, Kamal, Derkach, Andriy, Chan, Alexander, Xiao, Wenbin, Glass, Jacob, King, Amber C., Daniyan, Anthony F., Famulare, Christopher, Cuello, Bernadette M., Horvat, Troy Z., Abdel-Wahab, Omar, Levine, Ross L., Viny, Aaron D., Stein, Eytan M., Cai, Sheng F., Roshal, Mikhail, Tallman, Martin S., and Goldberg, Aaron D.

Published
2021
Full Text
View/download PDF

14. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Author

Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, and Mascarenhas, John

Published
2020
Full Text
View/download PDF

22. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy

Author

Zuanelli Brambilla, Corrado, Lobaugh, Stephanie M., Ruiz, Josel D., Dahi, Parastoo B., Goldberg, Aaron D., Young, James W., Gyurkocza, Boglarka, Shaffer, Brian C., Ponce, Doris M., Tamari, Roni, Sanchez Escamilla, Miriam, Castillo Flores, Nerea, Politikos, Ioannis, Scordo, Michael, Shah, Gunjan L., Cho, Christina, Lin, Richard J., Maloy, Molly A., Devlin, Sean M., Jakubowski, Ann A., Berman, Ellin, Stein, Eytan M., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Tallman, Martin S., Giralt, Sergio A., and Smith, Melody

Published
2021
Full Text
View/download PDF

23. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

25. Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Author

Cai, Sheng F., primary, Chu, S. Haihua, primary, Goldberg, Aaron D., primary, Parvin, Salma, primary, Koche, Richard P., primary, Glass, Jacob L., primary, Stein, Eytan M., primary, Tallman, Martin S., primary, Sen, Filiz, primary, Famulare, Christopher A., primary, Cusan, Monica, primary, Huang, Chun-Hao, primary, Chen, Chun-Wei, primary, Zou, Lihua, primary, Cordner, Keith B., primary, DelGaudio, Nicole L., primary, Durani, Vidushi, primary, Kini, Mitali, primary, Rex, Madison, primary, Tian, Helen S., primary, Zuber, Johannes, primary, Baslan, Timour, primary, Lowe, Scott W., primary, Rienhoff, Hugh Y., primary, Letai, Anthony, primary, Levine, Ross L., primary, and Armstrong, Scott A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Author

Cai, Sheng F., primary, Chu, S. Haihua, primary, Goldberg, Aaron D., primary, Parvin, Salma, primary, Koche, Richard P., primary, Glass, Jacob L., primary, Stein, Eytan M., primary, Tallman, Martin S., primary, Sen, Filiz, primary, Famulare, Christopher A., primary, Cusan, Monica, primary, Huang, Chun-Hao, primary, Chen, Chun-Wei, primary, Zou, Lihua, primary, Cordner, Keith B., primary, DelGaudio, Nicole L., primary, Durani, Vidushi, primary, Kini, Mitali, primary, Rex, Madison, primary, Tian, Helen S., primary, Zuber, Johannes, primary, Baslan, Timour, primary, Lowe, Scott W., primary, Rienhoff, Hugh Y., primary, Letai, Anthony, primary, Levine, Ross L., primary, and Armstrong, Scott A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 2 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Author

Cai, Sheng F., primary, Chu, S. Haihua, primary, Goldberg, Aaron D., primary, Parvin, Salma, primary, Koche, Richard P., primary, Glass, Jacob L., primary, Stein, Eytan M., primary, Tallman, Martin S., primary, Sen, Filiz, primary, Famulare, Christopher A., primary, Cusan, Monica, primary, Huang, Chun-Hao, primary, Chen, Chun-Wei, primary, Zou, Lihua, primary, Cordner, Keith B., primary, DelGaudio, Nicole L., primary, Durani, Vidushi, primary, Kini, Mitali, primary, Rex, Madison, primary, Tian, Helen S., primary, Zuber, Johannes, primary, Baslan, Timour, primary, Lowe, Scott W., primary, Rienhoff, Hugh Y., primary, Letai, Anthony, primary, Levine, Ross L., primary, and Armstrong, Scott A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Author

Cai, Sheng F., primary, Chu, S. Haihua, primary, Goldberg, Aaron D., primary, Parvin, Salma, primary, Koche, Richard P., primary, Glass, Jacob L., primary, Stein, Eytan M., primary, Tallman, Martin S., primary, Sen, Filiz, primary, Famulare, Christopher A., primary, Cusan, Monica, primary, Huang, Chun-Hao, primary, Chen, Chun-Wei, primary, Zou, Lihua, primary, Cordner, Keith B., primary, DelGaudio, Nicole L., primary, Durani, Vidushi, primary, Kini, Mitali, primary, Rex, Madison, primary, Tian, Helen S., primary, Zuber, Johannes, primary, Baslan, Timour, primary, Lowe, Scott W., primary, Rienhoff, Hugh Y., primary, Letai, Anthony, primary, Levine, Ross L., primary, and Armstrong, Scott A., primary

Published
2023
Full Text
View/download PDF

30. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

Author

McCarter, Joseph GW., primary, Nemirovsky, David, additional, Famulare, Christopher A., additional, Farnoud, Noushin, additional, Mohanty, Abhinita S., additional, Stone-Molloy, Zoe S., additional, Chervin, Jordan, additional, Ball, Brian J., additional, Epstein-Peterson, Zachary D., additional, Arcila, Maria E., additional, Stonestrom, Aaron J., additional, Dunbar, Andrew, additional, Cai, Sheng F., additional, Glass, Jacob L., additional, Geyer, Mark B., additional, Rampal, Raajit K., additional, Berman, Ellin, additional, Abdel-Wahab, Omar I., additional, Stein, Eytan M., additional, Tallman, Martin S., additional, Levine, Ross L., additional, Goldberg, Aaron D., additional, Papaemmanuil, Elli, additional, Zhang, Yanming, additional, Roshal, Mikhail, additional, Derkach, Andriy, additional, and Xiao, Wenbin, additional

Published
2022
Full Text
View/download PDF

31. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia

Author

Badar, Talha, primary, Litzow, Mark R., additional, Shallis, Rory M., additional, Patel, Anand, additional, Saliba, Antoine N., additional, Burkart, Madelyn, additional, Bewersdorf, Jan P., additional, Stahl, Maximilian, additional, De Camargo Correia, Guilherme Sacchi, additional, Guru Murthy, Guru Subramanian, additional, Abaza, Yasmin, additional, Duvall, Adam, additional, Bradshaw, Danielle, additional, Kota, Vamsi, additional, Dinner, Shira, additional, Goldberg, Aaron D., additional, Palmisiano, Neil, additional, Al Kali, Aref, additional, and Atallah, Ehab, additional

Published
2022
Full Text
View/download PDF

32. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia

Author

Przespolewski, Amanda, primary, Goldberg, Aaron D, additional, Talati, Chetasi, additional, Fazal, Salman, additional, Vachhani, Pankit, additional, Sanikommu, Srinivasa Reddy, additional, Thota, Swapna, additional, Waksal, Julian A., additional, Ball, Brian John, additional, Famulare, Christopher A, additional, Stahl, Maximilian, additional, Baron, Jeffrey, additional, Griffiths, Elizabeth A, additional, Thompson, James E., additional, Sweet, Kendra L, additional, and Wang, Eunice S., additional

Published
2022
Full Text
View/download PDF

33. Safety and efficacy of CPX-351 in younger patients (

Author

Przespolewski, Amanda, Goldberg, Aaron D., Talati, Chetasi, Fazal, Salman, Vachhani, Pankit, Sanikommu, Srinivasa R., Thota, Swapna, Waksal, Julian, Ball, Brian, Famulare, Christopher, Stahl, Maximilian, Baron, Jeffrey, Griffiths, Elizabeth A., Thompson, James E., Sweet, Kendra, and Wang, Eunice S.

Published
2023
Full Text
View/download PDF

34. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Author

Winer, Eric S., primary, Flamand, Yael, additional, Shallis, Rory Michael, additional, Stempel, Jessica M., additional, Goldberg, Aaron D, additional, Stahl, Maximilian F., additional, Patel, Anand Ashwin, additional, Duvall, Adam S, additional, Abaza, Yasmin, additional, Seijung Oh, Timothy, additional, Ma, Karen, additional, Badar, Talha, additional, Litzow, Mark R., additional, Kota, Vamsi, additional, Bradshaw, Danielle, additional, Raman, Hari S., additional, Luskin, Marlise R., additional, Stone, Richard M., additional, and DeAngelo, Daniel J., additional

Published
2022
Full Text
View/download PDF

35. A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Author

Goldberg, Aaron D, primary, Ohanian, Maro, additional, Koller, Paul B., additional, Cherry, Mohamad, additional, Altman, Jessica K., additional, Tomlinson, Benjamin, additional, Chandhok, Namrata Sonia, additional, Nguyen Haney, Donna, additional, Hu, Jia, additional, Sinha, Ranjeet Kumar, additional, Rice, William G, additional, and Bejar, Rafael, additional

Published
2022
Full Text
View/download PDF

36. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Shallis, Rory Michael, additional, Saliba, Antoine N., additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Grenet, Justin, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Kubiak, Michal Jakub, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

37. Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

Author

Dilip, Deepika, primary, Derkach, Andriy, additional, Menghrajani, Kamal, additional, Goldberg, Aaron D, additional, May, Hannah, additional, Klimek, Virginia M., additional, Galera, Pallavi K, additional, Xiao, Wenbin, additional, Zhang, Yanming, additional, Elemento, Olivier, additional, Levine, Ross L., additional, and Glass, Jacob L, additional

Published
2022
Full Text
View/download PDF

38. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Saliba, Antoine N., additional, Shallis, Rory Michael, additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Sacchi De Camargo Correia, Guillerhme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

39. Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Author

Robinson, Troy, primary, Bowman, Robert L., additional, Persaud, Sonali, additional, Liu, Ying, additional, Gao, Qi, additional, Zhang, Jing-Ping, additional, Sun, Xiaotian, additional, Sciambi, Adam, additional, Llanso, Aaron, additional, Famulare, Christopher, additional, Goldberg, Aaron D, additional, Dogan, Ahmet, additional, Roshal, Mikhail, additional, Levine, Ross L., additional, and Xiao, Wenbin, additional

Published
2022
Full Text
View/download PDF

40. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Author

Wolach, Ofir, primary, Garcia, Jacqueline S., additional, Desai, Pinkal, additional, Vachhani, Pankit, additional, Zeidner, Joshua F., additional, Abedin, Sameem, additional, Sweet, Kendra, additional, Lai, Catherine, additional, Moshe, Yakir, additional, Pollyea, Daniel A., additional, Xavier, Marin, additional, Nachmias, Boaz, additional, Zuckerman, Tsila, additional, Lee, Sangmin, additional, Chen, Evan C., additional, Bathini, Srilakshmi, additional, Edwards, Wesleigh, additional, Bui, Cat N., additional, Cheng, Wei-Han, additional, Miller, Catherine, additional, Guerin, Annie, additional, Maitland, Jessica, additional, Ma, Esprit, additional, Montez, Melissa, additional, Grunspan, Moshe, additional, and Goldberg, Aaron D, additional

Published
2022
Full Text
View/download PDF

41. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Author

Stahl, Maximilian, primary, Derkach, Andriy, additional, Farnoud, Noushin, additional, Bewersdorf, Jan Philipp, additional, Robinson, Troy, additional, Famulare, Christopher, additional, Cho, Christina, additional, Devlin, Sean, additional, Menghrajani, Kamal, additional, Patel, Minal A., additional, Cai, Sheng F., additional, Miles, Linde A., additional, Bowman, Robert L., additional, Geyer, Mark B., additional, Dunbar, Andrew, additional, Epstein‐Peterson, Zachary D., additional, McGovern, Erin, additional, Schulman, Jessica, additional, Glass, Jacob L., additional, Taylor, Justin, additional, Viny, Aaron D., additional, Stein, Eytan M., additional, Getta, Bartlomiej, additional, Arcila, Maria E., additional, Gao, Qi, additional, Barker, Juliet, additional, Shaffer, Brian C., additional, Papadopoulos, Esperanza B., additional, Gyurkocza, Boglarka, additional, Perales, Miguel‐Angel, additional, Abdel‐Wahab, Omar, additional, Levine, Ross L., additional, Giralt, Sergio A., additional, Zhang, Yanming, additional, Xiao, Wenbin, additional, Pai, Nidhi, additional, Papaemmanuil, Elli, additional, Tallman, Martin S., additional, Roshal, Mikhail, additional, and Goldberg, Aaron D., additional

Published
2022
Full Text
View/download PDF

42. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

Author

Bewersdorf, Jan Philipp, primary, Shallis, Rory M., additional, Derkach, Andriy, additional, Goldberg, Aaron D., additional, Stein, Anthony, additional, Stein, Eytan M., additional, Marcucci, Guido, additional, Zeidan, Amer M., additional, Shimony, Shai, additional, DeAngelo, Daniel J., additional, Stone, Richard M., additional, Aldoss, Ibrahim, additional, Ball, Brian J., additional, and Stahl, Maximilian, additional

Published
2022
Full Text
View/download PDF

43. Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)

Author

Stahl, Maximilian, primary, Shallis, Rory M., additional, Derkach, Andriy, additional, Goldberg, Aaron D., additional, Stein, Anthony, additional, Stein, Eytan M., additional, Marcucci, Guido, additional, Zeidan, Amer M., additional, Shimony, Shai, additional, DeAngelo, Daniel J., additional, Stone, Richard M., additional, Aldoss, Ibrahim, additional, Ball, Brian J., additional, and Bewersdorf, Jan Phillip, additional

Published
2022
Full Text
View/download PDF

46. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia.

Author

Badar, Talha, Litzow, Mark R., Shallis, Rory M., Patel, Anand, Saliba, Antoine N., Burkart, Madelyn, Bewersdorf, Jan P., Stahl, Maximilian, De Camargo Correia, Guilherme Sacchi, Guru Murthy, Guru Subramanian, Abaza, Yasmin, Duvall, Adam, Bradshaw, Danielle, Kota, Vamsi, Dinner, Shira, Goldberg, Aaron D., Palmisiano, Neil, Al Kali, Aref, and Atallah, Ehab

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, BLACK people, HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies
Abstract

Background: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies, the authors sought to explore disparities among patients with TP53‐mutated AML. Methods: A multicenter, retrospective study was conducted in a cohort of 340 patients who had TP53‐mutated AML (275 non‐Hispanic White [NHW] and 65 non‐Hispanic Black [NHB]) to analyze differences in treatment and outcome among NHW and NHB patients. Results: The median patient age was comparable between NHW and NHB patients (p =.76). A higher proportion of NHB patients had therapy‐related AML (31% vs. 20%; p =.08) and had co‐mutations (74% vs. 61%; p =.06). A higher proportion of NHW patients received intensive chemotherapy compared with NHB patients (47% vs. 31%; p =.02). Conversely, a higher proportion of NHB patients received low‐intensity chemotherapy (9% vs. 5.5%; p =.02) or best supportive care (22% vs. 7%; p <.001). The complete response rate (including complete responses with or without complete count recovery) was 31% versus 24.5% (p =.39) in NHW and NHB patients, respectively. Only 5% of NHB patients received allogeneic stem cell transplantation compared with 15.5% of NHW patients (p =.02). The proportion of patients who were event‐free (18.5% vs. 8.5%; p =.49) or who remained alive (24.9% vs. 8.3%; p =.13) at 18 months was numerically higher in NHW versus NHB patients, respectively, but was not statistically significant. Conclusions: The current study highlights disparities between NHW and NHB patients with TP53‐mutated AML. Efforts are warranted to eliminate treatment disparities in minority populations. Non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia (AML) were more likely to have concurrent mutations and therapy‐related AML than non‐Hispanic White patients. Non‐Hispanic Black patients who had TP53‐mutated AML received disease‐directed therapies less often compared with non‐Hispanic White patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia

Author

Prebet, Thomas, primary, Goldberg, Aaron D., additional, Jurcic, Joseph G., additional, Khaled, Samer, additional, Dail, Monique, additional, Feng, Yuning, additional, Green, Cherie, additional, Li, Chunze, additional, Ma, Connie, additional, Medeiros, Bruno C., additional, Yan, Mark, additional, and Grunwald, Michael R., additional

Published
2022
Full Text
View/download PDF

48. Outcomes ofTP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory M., additional, Goldberg, Aaron D., additional, Patel, Anand, additional, Abaza, Yasmin, additional, Bewersdorf, Jan P., additional, Saliba, Antoine N., additional, Correia, Guilherme Sacchi De Camargo, additional, Murthy, Guru, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Stahl, Maximilian, additional, Liu, Yuanhang, additional, Dinner, Shira, additional, Palmisiano, Neil, additional, Litzow, Mark R., additional, and Foran, James M., additional

Published
2022
Full Text
View/download PDF

49. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.

Author

Bewersdorf, Jan Philipp, Shallis, Rory M., Derkach, Andriy, Goldberg, Aaron D., Stein, Anthony, Stein, Eytan M., Marcucci, Guido, Zeidan, Amer M., Shimony, Shai, DeAngelo, Daniel J., Stone, Richard M., Aldoss, Ibrahim, Ball, Brian J., and Stahl, Maximilian

Subjects
CYTARABINE, ACUTE myeloid leukemia, SALVAGE therapy, VENETOCLAX, OVERALL survival
Abstract

FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with hypomethylating agents or low-dose cytarabine have expanded treatment options for patients with acute myeloid leukemia (AML). However, little data exist on the efficacy of venetoclax-based therapies in AML patients previously treated with FLT3 or IDH1/2 inhibitors. In this multicenter, retrospective cohort study, we included 44 patients who received venetoclax-based therapy after FLT3, IDH1 or IDH2 inhibitors. The overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 56.8% (18.2% CR) and a median overall survival of 9.2 months. While 6 out of 7 patients with IDH1 mutations who had previously been treated with ivosidenib responded to venetoclax-based therapy, FLT3-ITD mutations were associated with a lower response rate. Our data suggest that venetoclax can be an effective salvage therapy in patients previously treated with IDH1/2 or FLT3 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Author

Garcia, Jacqueline S., primary, Wolach, Ofir, additional, Vachhani, Pankit, additional, Zeidner, Joshua F., additional, Talati, Chetasi, additional, Pollyea, Daniel A., additional, Lai, Catherine, additional, Moshe, Yakir, additional, Abedin, Sameem, additional, Lavie, David, additional, Zuckerman, Tsila, additional, Xavier, Marin, additional, Lee, Sangmin, additional, Edwards, Wesleigh, additional, Chen, Evan, additional, Bui, Cat N., additional, Svensson, Anders, additional, Burne, Rebecca, additional, Kye, Steve, additional, Maitland, Jessica, additional, Ma, Esprit, additional, Montez, Melissa, additional, Grunspan, Moshe, additional, and Goldberg, Aaron D, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results